Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Navigation/Suche
- Forscher*innen
- Institutionen
- Projekte
- Publikationen
- Partner
- Geldgeber
- Ausstattung
- Knowhow
- Forschungsfelder
"Köpfe" der aktuellen Meldungen:
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Meisner, F; Walcher, D; Gizard, F; Kapfer, X; Huber, R; Noak, A; Sunder-Plassmann, L; Bach, H; Haug, C; Bachem, M; Stojakovic, T; März, W; Hombach, V; Koenig, W; Staels, B; Marx, N.
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Arterioscler Thromb Vasc Biol. 2006; 26(4):845-850
Doi: 10.1161/01.ATV.0000203511.66681.7f
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- März Winfried
- Stojakovic Tatjana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background - Therapeutic strategies to stabilize advanced arteriosclerotic lesions may prevent plaque rupture and reduce the incidence of acute coronary syndromes. Thiazolidinediones (TZDs), like rosiglitazone, are oral antidiabetic drugs with additional antiinflammatory and potential antiatherogenic properties. In a randomized, placebo-controlled, single-blind trial, we examined the effect of 4 weeks of rosiglitazone therapy on histomorphological characteristics of plaque stability in artery specimen of nondiabetic patients scheduled for elective carotid endarterectomy. Methods and Results - A total of 24 nondiabetic patients with symptomatic carotid artery stenosis were randomly assigned to rosiglitazone (4 mg BID) or placebo in addition to standard therapy. In this population of nondiabetic patients, rosiglitazone treatment did not significantly change fasting blood glucose, fasting insulin, or lipid parameters. In contrast, rosiglitazone significantly reduced CD4-lymphocyte content as well as macrophage HLA-DR expression in the shoulder region, reflecting less inflammatory activation of these cells by lymphocyte interferon-gamma. Moreover, rosiglitazone significantly increased plaque collagen content (7.7 +/- 1.6% versus 3.7 +/- 0.7% of plaque area; P = 0.036) compared with placebo, suggesting that TZD treatment may stabilize arteriosclerotic lesions. In addition, rosiglitazone reduced serum levels of 2 inflammatory arteriosclerosis markers: C-reactive protein and serum amyloid A. Conclusions - Four weeks of treatment with rosiglitazone significantly reduces vascular inflammation in nondiabetic patients, leading to a more stable type of arteriosclerotic lesion.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Blood Glucose - drug effects
- Body Mass Index -
- C-Reactive Protein - metabolism
- Carotid Stenosis - drug therapy Carotid Stenosis - metabolism Carotid Stenosis - physiopathology
- Cholesterol - blood
- Cholesterol, HDL - blood
- Cholesterol, LDL - blood
- Collagen - metabolism
- Diabetes Mellitus -
- Female -
- Humans -
- Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use
- Inflammation - drug therapy
- Insulin - blood
- Male -
- Middle Aged -
- Serum Amyloid A Protein - metabolism
- Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use
- Find related publications in this database (Keywords)
- plaque
- thiazolidinediones
- inflammation
- collagen
- diabetes